Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

The Clinical Spectrum of Acute GVHD: Beyond Day 100.

Daniel R. Couriel, MD, Rima Saliba, PhD, Shubhra Gosh, MD, Marcos De Lima, MD, Sergio Giralt, MD, Issa Khouri, MD, Borje Andersson, MD, Kerry Mickler, RN, Zuraima Caldera, MD, Yvonne Hsu, PAC, Joyce Neumann, RN, APN, Sharon Hymes, MD, Stella Kim, MD, Richard Champlin, MD

Blood (2005) 106 (11): 5377.

https://doi.org/10.1182/blood.V106.11.5377.5377

Published: 2005

Journal Articles

Clinical, Prognostic and Therapeutic Implications in the Diagnosis of Grade I Acute Graft-Versus-Host Disease.

Rima M. Saliba, PhD, Marcos de Lima, MD, Chitra Hosing, MD, Issa F. Khouri, MD, Sergio Giralt, MD, Paolo Anderlini, MD, Shubhra Ghosh, MD, Kerry Mickler, RN, Cindy Ippoliti, PHARMD, Zuraima Caldera, MD, Yvonne Hsu, PAC, Joyce Neumann, APN, Richard Champlin, MD, Daniel R. Couriel, MD

Blood (2005) 106 (11): 1799.

https://doi.org/10.1182/blood.V106.11.1799.1799

Published: 2005

Journal Articles

Phase II/III Randomized Study Comparing Two Different Tacrolimus Blood Levels for the Prevention of Graft-Versus-Host Disease (GVHD).

Daniel R. Couriel, MD, Peter Thall, PhD, Kerry Mickler, RN, Marcos De Lima, MD, Sergio Giralt, MD, Muzaffar H. Qazilbash, MD, Chitra Hosing, MD, Issa Khouri, MD, Partow Kebriaei, MD, Yvonne Hsu, MD, Rima Saliba, MD, Cindy Ippoliti, PharmD, Richard Champlin, MD

Blood (2005) 106 (11): 142.

https://doi.org/10.1182/blood.V106.11.142.142

Published: 2005

Journal Articles

Results of Bortezomib (BTZ) Therapy for Myeloma (MM) Patients Relapsing after an Allogeneic Transplant. Preliminary Results Show Efficacy without Induction of GVHD.

Sergio Giralt, MD, Ana Aleman, MD, Xin Lei, MD, Marilyn Davis, RN, Kerry Mickler, RN, Donna Weber, MD, Michael Wang, MD, Richard Champlin, MD

Blood (2004) 104 (11): 1651.

https://doi.org/10.1182/blood.V104.11.1651.1651

Published: 2004

Journal Articles

Hyperacute Graft-Versus-Host Disease: Analysis of Risk Factors, Clinical Manifestations and Outcomes.

Daniel R. Couriel, MD, Rima Saliba, PhD, Marcos J. de Lima, MD, Chitra Hosing, MD, Borje Andersson, MD, Jorge De Jesus, RN, Kerry Mickler, RN, Yvonne Hsu, PA, Elizabeth J. Shpall, MD, Shubhra Ghosh, MD, Richard Champlin, MD

Blood (2004) 104 (11): 734.

https://doi.org/10.1182/blood.V104.11.734.734

Published: 2004

NARROW

The Clinical Spectrum of Acute GVHD: Beyond Day 100.

Clinical, Prognostic and Therapeutic Implications in the Diagnosis of Grade I Acute Graft-Versus-Host Disease.

Phase II/III Randomized Study Comparing Two Different Tacrolimus Blood Levels for the Prevention of Graft-Versus-Host Disease (GVHD).

Results of Bortezomib (BTZ) Therapy for Myeloma (MM) Patients Relapsing after an Allogeneic Transplant. Preliminary Results Show Efficacy without Induction of GVHD.

Hyperacute Graft-Versus-Host Disease: Analysis of Risk Factors, Clinical Manifestations and Outcomes.

Email alerts

ASH Publications

American Society of Hematology

The Clinical Spectrum of Acute GVHD: Beyond Day 100.

Clinical, Prognostic and Therapeutic Implications in the Diagnosis of Grade I Acute Graft-Versus-Host Disease.

Phase II/III Randomized Study Comparing Two Different Tacrolimus Blood Levels for the Prevention of Graft-Versus-Host Disease (GVHD).

Results of Bortezomib (BTZ) Therapy for Myeloma (MM) Patients Relapsing after an Allogeneic Transplant. Preliminary Results Show Efficacy without Induction of GVHD.

Hyperacute Graft-Versus-Host Disease: Analysis of Risk Factors, Clinical Manifestations and Outcomes.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only